Resumo

GONZALEZ MUNGUIA, Silvia et al. Etanercept on steroid-refractary acute graft-versus-host disease. Farm Hosp. [online]. 2015, vol.39, n.3, pp.147-151. ISSN 2171-8695.  https://dx.doi.org/10.7399/fh.2015.39.3.8000.

Objetive: To describe etanercept use and effectiveness on steroid-refractary acute graft-versus-host disease after hematopoietic cell transplantation. Method: Patients treated with etanercept as off label use for steroid-refractary acute graft-versus-host disease were selected and each patient's medical history was reviewed to assess the clinical response. Results: The study included five patients: four presented with digestive manifestations and one presented pulmonary and liver manifestations. 80% of patients showed a clinical response: 60% a partial response and 20% a total response. In four cases etanercept 25mg was administered twice a week with variable duration of treatment, achieving no response in 1 case (3 weeks), partial response in two 2 cases (4 weeks and 8 weeks) and a complete response in 1 case (8 week period). Only one case was treated with etanercept 50mg administered twice a week for 5 weeks with a partial treatment response. Conclusions: The clinical response rate is consistent with the previously published data. This updates the scarce bibliographic information about etanecept use in steroid-refractary acute graft-versus-host disease. Due to clinical design limitations and the small patient population, future clinical studies should be conducted to assess the efficacy and security of etanercept in these patients.

Palavras-chave : Etanercept; Graft-versus-host; Steroid-refractary; Hematopoietic cell; Transplantation.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )